Denosumab Plus Immune Checkpoint Inhibitors in Bone Metastases From Solid Tumors

Area of Science:

• Oncology
• Immunology
• Bone Metastasis Research

Background:

• Bone metastases significantly worsen prognosis and quality of life in advanced solid tumors.
• Immune checkpoint inhibitors (ICIs) and bone-targeted therapies are emerging strategies for bone metastases.
• Denosumab, an anti-RANKL mAb, inhibits bone resorption and modulates the immune microenvironment.

Purpose of the Study:

• To review preclinical and clinical findings on the combination of denosumab and ICIs for bone metastases.
• To discuss potential biomarkers and challenges for optimizing patient selection and therapy.
• To overview ongoing studies investigating the antitumor synergy of this combination.

Main Methods:

• Narrative review of existing preclinical and clinical data.
• Analysis of mechanistic insights into the synergistic effects of denosumab and ICIs.
• Summary of ongoing clinical trials and future research directions.

Main Results:

• Denosumab enhances anti-tumor immunity by modulating the bone microenvironment and improving vascular integrity.
• ICIs restore T-cell activity, overcoming tumor-induced immune suppression.
• Emerging evidence suggests synergy between denosumab and ICIs, potentially by reinvigorating T-cell function and dendritic cell activity.

Conclusions:

• The combination of denosumab and ICIs presents a promising therapeutic strategy for bone metastases.
• Further research is needed to identify optimal patient selection criteria and therapeutic paradigms.
• Ongoing studies are crucial for validating the antitumor synergy and clinical benefits of this combination.